1.
Rule S, Barreto WG, Briones J, Carella AM, Casasnovas O, Pocock C, Wendtner C-M, Zaja F, Robson S, MacGregor L, Tschopp RR, Nick S, Dreyling M. Efficacy and safety assessment of prolonged maintenance with subcutaneous rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results of the Phase III MabCute study. Haematologica; https://doi.org/10.3324/haematol.2020.274803 [Early view].